


AMENDMENTS TO THE CLAIMS:

The following listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-10 (canceled)

Claim 11 (currently amended): A suspension concentrate comprising

- (a) at least one active compound that is solid at room temperature selected from the group consisting of azoles and strobilurins,
- (b) at least one penetration enhancer selected from the group consisting of alkanolethoxylates of formula (I)



wherein

m represents numbers from 9 to 17, and

n represents numbers from 8 to 16,

- (c) at least one dispersant selected from the group consisting of (i) polymers of methyl 2-methyl-2-propenoate and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxy poly(oxy-1,2-ethanediyl), (ii) tristyrylphenolethoxylates, and (iii) propylene oxide/ethylene oxide block copolymers having molecular weights between 8000 and 10,000
 - (i) a polymer of methyl 2-methyl-2-propenoate and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxypoly(oxy-1,2-ethanediyl) (CAS No. 111 740-36-4) and a tristyrylphenolethoxylate having an average of 50 to 60 oxyethylene units,
 - (ii) a polymer of methyl 2-methyl-2-propenoate and α -(2-methyl-1-oxo-2-propenyl)- ω -methoxypoly(oxy-1,2-ethanediyl) (CAS No. 111 740-36-4) and a propylene oxide/ethylene oxide block copolymer having a molecular weight between 8000 and 10,000 and an ethylene oxide proportion of between 40 and 60% by weight, and
 - (iii) a tristyrylphenolethoxylate having an average of 50 to 60 oxyethylene units and a propylene oxide/ethylene oxide block copolymer having a

molecular weight between 8000 and 10,000 and an ethylene oxide proportion of between 40 and 60% by weight ,

- (d) water, and
- (e) optionally, one or more additives.

Claim 12 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is one or more triazoles selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, paclebutrazol, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetaconazole, triadimefon, triadimenol, and triticonazole and/or one or more imidazoles selected from the group consisting of imazalil, oxpoconazole fumarate, peforazoate, prochloraz, and triflumizole.

Claim 13 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is one or more strobilurins selected from the group consisting of azoxystrobin, dimoxystrobin, famoxadone, fenamidone, fluoxastrobin, kresoxim-methyl, metaminostrobin, picoxystrobin, pyraclostrobin, and trifloxystrobin.

Claim 14 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is tebuconazole.


Claim 15 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) comprises tebuconazole and trifloxystrobin.

Claim 16 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) comprises prothioconazole and fluoxastrobin.

Claim 17 (previously presented): A suspension concentrate according to Claim 11 wherein component (a) is trifloxystrobin.

Claims 18-20 (canceled)

Claim 21 (previously presented): A suspension concentrate according to Claim 11 wherein component (b) is an alkanolethoxylate of formula (I)



wherein

m represents numbers from 9 to 13, and

n represents numbers from 8 to 12.

Claim 22 (previously presented): A suspension concentrate according to Claim 11 wherein m represents 11 and n represents 10.

Claims 23-24 (canceled)